Eiger BioPharmaceuticals to Ho - GuruFocus.com
GuruFocus Article or News written by PRNewswire and the topic is about:
Source: gurufocus.com
Page 6 - Peginterferon Lambda News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peginterferon Lambda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peginterferon Lambda Today - Breaking & Trending Today
Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event on Hepatitis Delta Virus Monday, November 15
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Source: prnewswire.com
Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event on Hepatitis Delta Virus Monday, November 15
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Eiger to add Peginterferon Lambda to Covid-19 trial in Brazil
Eiger to add Peginterferon Lambda to Covid-19 trial in Brazil 04 May 2021 (Last Updated May 4th, 2021 12:09) Eiger BioPharmaceuticals has said that its investigational agent, Peginterferon Lambda, will be added to the Phase III TOGETHER platform study of Covid-19 outpatients in Brazil. Share Article The study is enrolling Covid-19 patients at 11 sites in Brazil. Credit: Wilfried Pohnke from Pixabay. Eiger BioPharmaceuticals has said that its investigational agent, Peginterferon Lambda, will be added to the Phase III TOGETHER platform study o...
Source: clinicaltrialsarena.com
Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in Brazil
Share this article Share this article PALO ALTO, Calif., May 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Peginterferon Lambda (Lambda) will be added to the ongoing, multi-center, Phase 3 TOGETHER platform study in outpatients with COVID-19. TOGETHER is an ongoing, multi-center, investigator-sponsored, randomized, placebo-controlled Phase 3 study evaluating multiple therapeutics in newly d...
Source: prnewswire.com